high mobility group nucleosome binding domain 1 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored HMGN1P4 profile across patient tissues and cancer cell-line models. HMGN1P4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HMGN1P4 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, HMGN1P4 RNA expression shows 12,188 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, BRCA, and THYM as cancer lineages where HMGN1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN1P4 survival associations across molecular data types. HMGN1P4 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN1P4 RNA expression–survival associations across cancer types. High HMGN1P4 expression shows unfavorable associations in ACC, LIHC and STAD, but favorable associations in SKCM, BLCA and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HMGN1P4 RNA expression.
This table summarizes HMGN1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN1P4 shows higher tumor expression in BRCA, LUAD, BLCA, LIHC, CHOL and LUSC. The BRCA box plot shows higher HMGN1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.728, t-test p < 0.001).
This table shows molecular features associated with HMGN1P4 in patient tissues and cancer cell lines. In patient samples, HMGN1P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
